HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tylophorine, a phenanthraindolizidine alkaloid isolated from Tylophora indica exerts antiangiogenic and antitumor activity by targeting vascular endothelial growth factor receptor 2-mediated angiogenesis.

AbstractBACKGROUND:
Anti-angiogenesis targeting VEGFR2 has been considered as an important strategy for cancer therapy. Tylophorine is known to possess anti-inflammatory and antitumor activity, but its roles in tumor angiogenesis, the key step involved in tumor growth and metastasis, and the involved molecular mechanism is still unknown. Therefore, we examined its anti-angiogenic effects and mechanisms in vitro and in vivo.
METHODS:
We used tylophorine and analyzed its inhibitory effects on human umbilical vein endothelial cells (HUVEC) in vitro and Ehrlich ascites carcinoma (EAC) tumor in vivo.
RESULTS:
Tylophorine significantly inhibited a series of VEGF-induced angiogenesis processes including proliferation, migration, and tube formation of endothelial cells. Besides, it directly inhibited VEGFR2 tyrosine kinase activity and its downstream signaling pathways including Akt, Erk and ROS in endothelial cells. Using HUVECs we demonstrated that tylophorine inhibited VEGF-stimulated inflammatory responses including IL-6, IL-8, TNF-α, IFN-γ, MMP-2 and NO secretion. Tylophorine significantly inhibited neovascularization in sponge implant angiogenesis assay and also inhibited tumor angiogenesis and tumor growth in vivo. Molecular docking simulation indicated that tylophorine could form hydrogen bonds and aromatic interactions within the ATP-binding region of the VEGFR2 kinase unit.
CONCLUSION:
Tylophorine exerts anti-angiogenesis effects via VEGFR2 signaling pathway thus, may be a viable drug candidate in anti-angiogenesis and anti-cancer therapies.
AuthorsSarita Saraswati, Pawan K Kanaujia, Shakti Kumar, Ranjeet Kumar, Abdulqader A Alhaider
JournalMolecular cancer (Mol Cancer) Vol. 12 Pg. 82 (Jul 29 2013) ISSN: 1476-4598 [Electronic] England
PMID23895055 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Alkaloids
  • Angiogenesis Inhibitors
  • Antineoplastic Agents, Phytogenic
  • Cytokines
  • Indolizines
  • Phenanthrenes
  • Vascular Endothelial Growth Factor A
  • Nitric Oxide
  • Vascular Endothelial Growth Factor Receptor-2
  • Matrix Metalloproteinase 2
  • tylophorine
Topics
  • Alkaloids (administration & dosage, chemistry, pharmacology)
  • Angiogenesis Inhibitors (administration & dosage, chemistry, pharmacology)
  • Animals
  • Antineoplastic Agents, Phytogenic (administration & dosage, chemistry, pharmacology)
  • Cell Movement (drug effects)
  • Cell Proliferation (drug effects)
  • Cell Survival (drug effects)
  • Cytokines (metabolism)
  • Disease Models, Animal
  • Female
  • Human Umbilical Vein Endothelial Cells (drug effects, metabolism)
  • Humans
  • Indolizines (administration & dosage, chemistry, pharmacology)
  • Male
  • Matrix Metalloproteinase 2 (metabolism)
  • Mice
  • Molecular Conformation
  • Molecular Docking Simulation
  • Neoplasms (drug therapy, metabolism, mortality, pathology)
  • Neovascularization, Physiologic (drug effects)
  • Nitric Oxide (metabolism)
  • Phenanthrenes (administration & dosage, chemistry, pharmacology)
  • Protein Binding (drug effects)
  • Protein Interaction Domains and Motifs
  • Signal Transduction (drug effects)
  • Tumor Burden (drug effects)
  • Tylophora (chemistry)
  • Vascular Endothelial Growth Factor A (metabolism)
  • Vascular Endothelial Growth Factor Receptor-2 (antagonists & inhibitors, chemistry, metabolism)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: